In tumors with mixed fibrolamellar and conventional HCC features or suspected biologic mimics, what practical criteria do you use to determine (1) eligibility for fibrolamellar-specific trials, (2) how aggressive to be surgically, and (3) how strongly to favor checkpoint-based immunotherapy?